Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• PoundCRPartinAWEisenbergerMAChanDWPearsonJDWalshPCNatural history of progression after PSA elevation following radical prostatectomyJAMA1999281171591159710235151
   PubMed Web of Science ®Google Scholar
• UchioEMAslanMWellsCKCalderoneJConcatoJImpact of biochemical recurrence in prostate cancer among US veteransArch Intern Med2010170151390139520696967
   PubMedGoogle Scholar
• AntonarakisESTrockBJFengZThe natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-upJ Clin Oncol200927Suppl abstract 5008.
   Google Scholar
• D’AmicoAVCoteKLoffredoMRenshawAASchultzDDeterminants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancerJ Clin Oncol200220234567457312454114
   PubMed Web of Science ®Google Scholar
• TannockIFOsobaDStocklerMRChemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsJ Clin Oncol1996146175617648656243
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• FDA Center for Drug Evaluation and ResearchApproval Package for: Jevtana6172010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201023s000Approv.pdf. Accessed February 2, 2011.
   Google Scholar
• JordanMAWilsonLMicrotubules as a target for anticancer drugsNat Rev Cancer20044425326515057285
   PubMed Web of Science ®Google Scholar
• Sanofi-AventisJevtana prescribing information6172010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf. Accessed February 2, 2011.
   Google Scholar
• BradshawDMArceciRJClinical relevance of transmembrane drug efflux as a mechanism of multidrug resistanceJ Clin Oncol19981611367436909817290
   PubMed Web of Science ®Google Scholar
• BorstPEversRKoolMWijnholdsJA family of drug transporters: the multidrug resistance-associated proteinsJ Natl Cancer Inst200092161295130210944550
   PubMed Web of Science ®Google Scholar
• RowinskyEKSmithLWangYMPhase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRPJ Clin Oncol1998169296429769738565
   PubMed Web of Science ®Google Scholar
• MitaACDenisLJRowinskyEKPhase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsClin Cancer Res200915272373019147780
   PubMed Web of Science ®Google Scholar
• BatesSFChenCRobeyRKangMFiggWDFojoTReversal of multidrug resistance: lessons from clinical oncologyNovartis Found Symp2002243839611990784
   PubMedGoogle Scholar
• KingstonDGTubulin-interactive natural products as anticancer agentsJ Nat Prod200972350751519125622
   PubMed Web of Science ®Google Scholar
• WilkesGCabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancerOncology (Williston Park)20102410 Suppl464821275327
   PubMedGoogle Scholar
• PivotXKoralewskiPHidalgoJLA multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patientsAnn Oncol20081991547155218436520
   PubMed Web of Science ®Google Scholar
• De BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumorsEuropean Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• De BonoJSSartorOCabazitaxel for castration-resistant prostate cancer – author’s replyLancet20113779760122123
   Web of Science ®Google Scholar
• SartorOHalsteadMKatzLImproving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancerClin Genitourin Cancer201081232821208852
   PubMed Web of Science ®Google Scholar
• ShigetaKMiuraYNaitoYTakanoTCabazitaxel for castration-resistant prostate cancerLancet20113779760121 author reply12212321215876
   PubMed Web of Science ®Google Scholar
• PalSKTwardowskiPSartorOCritical appraisal of cabazitaxel in the management of advanced prostate cancerClin Interv Aging2010539540221152241
   PubMed Web of Science ®Google Scholar
• FroehnerMWirthMPCabazitaxel for castration-resistant prostate cancerLancet20113779760121122 author reply12212321215875
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• IMS MIDASIMS Health2010
   Google Scholar
• ManifoldCCabazitaxel (Jevtana): another arrow in the prostate cancer quiverInformulary20103612
   Google Scholar
• RamseySDClarkeLKamathTVLubeckDEvaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a US health insurance planJ Manag Care Pharm200612647247816925455
   PubMed Web of Science ®Google Scholar
• BaumASanofi-Aventis Sales Model for 2009–2016PallerCPrivate correspondence from Morgan Stanley Smith Barney, October 6, 2010 detailing the Sanofi-Aventis Sales Model for 2009–2016, prepared by Andrew Baum, European Pharmaceutical Analyst
   Google Scholar
• ScherHIBeerTMHiganoCSAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyLancet201037597241437144620398925
   PubMed Web of Science ®Google Scholar
• De BonoJSLogothetisCJFizaziKAbiraterone acetate plus low-dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase III study35th ESMO Congress2010 Oct 8–12Milan, ItalyAnn Oncol201021Suppl 8viii
   Google Scholar
• ChiKNHotteSJYuEYRandomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerJ Clin Oncol201028274247425420733135
   PubMed Web of Science ®Google Scholar
• KantoffPWSchuetzTJBlumensteinBAOverall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancerJ Clin Oncol20102871099110520100959
   PubMed Web of Science ®Google Scholar